Exclusive Summary

• Targeting US FDA ANDA filing in 2026, positioning it globally as a front-runner in the generic pipeline with massive first-to-market or early-launch advantages.
• Directly addressing the tremendous under-served market of tens of millions of patients with moderate-to-severe atopic dermatitis driven by high demand for oral targeted therapies.
• Developed strictly under top-tier US FDA standards, offering premium cGMP compliance to facilitate rapid regulatory registrations and market access across various regions.
• Providing robust full-dosage options (50mg/100mg/200mg) with a highly competitive cost advantage, enabling profound product penetration and lucrative margins for distribution partners.